[go: up one dir, main page]

NZ514990A - Releasable linkage and compositions containing same - Google Patents

Releasable linkage and compositions containing same

Info

Publication number
NZ514990A
NZ514990A NZ514990A NZ51499000A NZ514990A NZ 514990 A NZ514990 A NZ 514990A NZ 514990 A NZ514990 A NZ 514990A NZ 51499000 A NZ51499000 A NZ 51499000A NZ 514990 A NZ514990 A NZ 514990A
Authority
NZ
New Zealand
Prior art keywords
compositions containing
containing same
releasable linkage
aryl
alkyl
Prior art date
Application number
NZ514990A
Inventor
Samuel Zalipsky
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NZ514990A publication Critical patent/NZ514990A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Compounds of formula (I), wherein: R1 is a hydrophilic polymer comprising a linkage for attachment to the dibenzyl moiety, R2 is selected from H, alkyl and aryl, R3 is selected from O(C=O)R4, S(C=O)R4, and O(C=S)R4, R4 is an amine containing ligand, R5 is selected from H, alkyl and aryl, and the orientation of R3 is ortho or para. The compounds are used in to provide liposomes with improved blood circulation time.
NZ514990A 1999-04-23 2000-04-21 Releasable linkage and compositions containing same NZ514990A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13089799P 1999-04-23 1999-04-23
PCT/US2000/010830 WO2000064483A2 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same

Publications (1)

Publication Number Publication Date
NZ514990A true NZ514990A (en) 2004-01-30

Family

ID=34107071

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514990A NZ514990A (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same

Country Status (8)

Country Link
EP (1) EP1173221A2 (en)
JP (1) JP2002542386A (en)
AU (1) AU770390B2 (en)
CA (1) CA2368793A1 (en)
IL (1) IL146047A0 (en)
NO (1) NO20015169L (en)
NZ (1) NZ514990A (en)
WO (1) WO2000064483A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1173222T3 (en) 1999-04-23 2007-01-29 Alza Corp Conjugate with a cleavable bond for use in a liposome
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR100777195B1 (en) * 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 Delivery material and drug delivery system using the same
MXPA03008864A (en) * 2001-03-26 2004-12-06 Johnson & Johnson Liposome composition for improved intracellular delivery of a therapeutic agent.
US7696359B2 (en) * 2003-09-03 2010-04-13 Kyowa Hakko Kirin Co., Ltd. Compound modified with glycerol derivative
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
JP7022328B2 (en) 2017-03-30 2022-02-18 日油株式会社 Hydrophilic polymer derivative with self-destructive acetal linker and complex using it

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method

Also Published As

Publication number Publication date
WO2000064483A2 (en) 2000-11-02
NO20015169D0 (en) 2001-10-23
CA2368793A1 (en) 2000-11-02
AU770390B2 (en) 2004-02-19
AU4367200A (en) 2000-11-10
EP1173221A2 (en) 2002-01-23
NO20015169L (en) 2001-12-19
JP2002542386A (en) 2002-12-10
WO2000064483A3 (en) 2001-08-02
IL146047A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
DE122009000040I2 (en) Naphthalene derivatives, processes for their preparation and pharmaceutical compositions containing them.
EP0945764A3 (en) Photoresist composition
PT81910A (en) Process for preparing derivatives of imidazole and pharmaceutical compositions containing these derivatives
NZ514990A (en) Releasable linkage and compositions containing same
NZ505103A (en) Phenylaminoalkylcarboxylic acid derivatives useful as beta 3 adrenoceptor stimulants
NO915049L (en) INDENOINDOL COMPOUNDS II
JO1622B1 (en) Indenoindole compounds II
EP0281412A3 (en) Novel organic platinum complex pharmaceutical compositions containing same and a process for the preparation thereof
ES8604218A1 (en) Benzoquinolizines.
DE69901088D1 (en) 1,2-dithiolane derivatives, processes for their preparation and pharmaceutical compositions containing them
ATE69448T1 (en) QUINOLINECARBONIC ACID DERIVATIVES, THE COMPOSITION CONTAINING THEM, PROCESSES FOR THEIR MANUFACTURE AND THEIR USE IN THE MANUFACTURE OF MEDICATIONS.
ES2003086A6 (en) Sulphonamides.
EP0481370A3 (en) Use of phosphonic acid diglycidylesters as cross-linking agent in hydrogels
DK0413278T3 (en) Use of xanthine derivatives against peptic ulcer
JPS5528997A (en) Pyrano heterocyclic compound
DK280883A (en) ORGANOPHOSPHATE DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND THEIR USE AS MEASURES TO COMPLETE HARMFUL ORGANISMS
FR2550189B1 (en) NOVEL ACETYLENIC DERIVATIVES HAVING ACTIVITY OF ENZYME INHIBITORS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
DE68909961D1 (en) 2-aminoacetamide derivatives.
TH31631A (en) Optional Zen tag Procedures for the preparation and use of taxane as a therapeutic agent.
DE60007984D1 (en) Antioxidants, process for their preparation and their uses
TH54361A3 (en) Croman derivatives
GB2021587A (en) Benzoquinolizines
EP0358396A3 (en) Aquatic antifouling compositions
JPS5661352A (en) 3-oxy-beta-lactam compound
MY103558A (en) Fungicides

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)